NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 8 February 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Mariana Bacelar Present for all items
4. Maria Brezitski Present for all items
5. Professor Francis Drobniewski Present for all items
6. Dr Mark Glover Present for all items
7. Dr Bushra Hasnie Present for all items
8. Dr Veline L’Esperance Present for all items
9. Dr Warren Linley Items 5.1 to 5.3.2
10. Stella O’Brien Items 4.1 to 4.3.2
11. Malcolm Oswald Items 5.1 to 5.3.2
12. Dr Rhiannon Owen Present for all items
13. Anna Pracz Present for all items
14. Gabriel Rogers  Present for all items
15. Dr Toby Smith Present for all items
16. Mary Weatherstone Items 4.1 to 4.3.2
17. Professor Nicky Welton Present for all items
18. Nigel Westwood Present for all items
19. Peter Wheatley-Price Items 5.1 to 5.3.2
20. Dr Stuart Williams Present for all items
21. Tony Wootton Present for all items

NICE staff (key players) present

Henry Edwards, Associate Director  Items 5.1 to 5.3.2

Richard Diaz, Associate Director Items 4.1 to 4.3.2

Daniel Davies, Project Manager Items 5.1 to 5.3.2

Jeremy Powell, Project Manager Items 4.1 to 4.3.2

Yelen Guo, Heath Technology Assessment Adviser Items 4.1 to 4.3.2

Thomas Jarratt, Heath Technology Assessment Analyst Items 4.1 to 4.3.2

Rufaro Kausi, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

Victoria Gillis-Elliott, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

Philip Williams, Business Analyst, Resource Impact Present for all Items

Ella Fitzgerald, Public Involvement Adviser Present for all items

Denise Moyo, Coordinator, Committee Operations Present for all items

Wajeeha Asim, Administrator, Technology Appraisals Items 4.1 to 4.3.2

Rumana Zaman, Administrator, Technology Appraisals Items 5.1 to 5.3.2

NICE staff (observers) present

Sarah Wilkes, Technical Analyst, Technology Appraisals Present for all items

Catrin Austin, Technical Analyst, Commercial Liaison. Items 4.1 to 4.3.2

External assessment group representatives present

Jo Picot, Southampton HTA Items 4.1 to 4.3.2

Neelam Kalita, Southampton HTA Items 4.1 to 4.3.2

Maiwenn Ali, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.3.2

Robert Wolff, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.3.2

Clinical, Patient & NHS England experts present

Neil Rabin, Consultant Haematologist, Clinical Expert, Nominated by UK Myeloma Items 4.1 to 4.3.2

Karthik Ramasamy, Associate Professor of Haematology & Consultant Haematologist, Clinical Expert Oxford University & South Midlands Research Network Items 4.1 to 4.3.2

Shelagh McKinley, Acting Director of Research and Advocacy / Head of Patient Advocacy Patient Expert, Nominated by Myeloma UK Items 4.1 to 4.3.2

Rosie Dill, Patient Expert, Nominated by Myeloma UK Items 4.1 to 4.3.2

Dr Kieran McCafferty, Consultant Nephrologist Clinical Expert, Nominated by Specialised Commissioning, NHS England and Improvement Items 5.1 to 5.3.2

Professor Indranil Dasgupta, Consultant nephrologist, Clinical Expert, Nominated by UK Kidney Association (UKKA) Items 5.1 to 5.3.2

Faizan Awan, Patient representative, Patient Expert, Nominated by Kidney Research UK Items 5.1 to 5.3.2

George Lankester, Policy Manager, Patient Expert, Nominated by Kidney Research UK Items 5.1 to 5.3.2

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Alistair Patton, Mary Weatherstone, and Professor Iolo Doull

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 12 January 2023.
1. **Appraisal of** **Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma [ID4057]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Janssen.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Shelagh McKinley declared an indirect financial interest as Myleoma UK receives grant funding and occasional honoraria from submitting company as well companies that are comparators in this appraisal. It was agreed that his declaration would not prevent Shelagh McKinley from providing expert advice to the committee.
* Neil Rabin declared an indirect financial interest as he has received honoraria from several companies including Janssen. It was agreed that his declaration would not prevent Neil Rabin from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the evidence presented to the committee.. This information was presented to the committee by [Mary Weatherstone, Gabriel Rogers, Nigel Westwood].
	1. Part 2a – Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (company representatives, all professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG) or Draft Guidance (DG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) or Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11060> .
1. **Appraisal of** **Difelikefalin for treating pruritus in people having haemodialysis [ID3890]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Vifor Pharma UK.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* George Lancaster declared an indirect non-financial interest as he is part of the kidney research organisation has received funding from Vifor for clinical research project. It was agreed that his declaration would not prevent George Lancaster from providing expert advice to the committee.
* Kieran McCarthy declared a direct financial interest as he was the national coordinating investigators for one of the relevant researches in the topic called CDK. It was agreed that his declaration would not prevent Kieran McCarthy from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Rhiannon Owen, Tony Wootton, Veline L’Esperance].
	1. Part 2a - Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b - Closed session (company representatives, professional experts apart from Peter Clark NHS Expert, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG) or Draft Guidance (DG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) or Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <h[ttps://www.nice.org.uk/guidance/indevelopment/gid-ta10793](https://www.nice.org.uk/guidance/indevelopment/gid-ta10793) .

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 9 March 2023 and will start promptly at 9am.